...
首页> 外文期刊>Biomedicine & pharmacotherapy =: Biomedecine & pharmacotherapie >NLK, a novel target of miR-199a-3p, functions as a tumor suppressor in colorectal cancer
【24h】

NLK, a novel target of miR-199a-3p, functions as a tumor suppressor in colorectal cancer

机译:NLK是miR-199a-3p的新型靶标,在大肠癌中起抑癌作用

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

We previously reported that miR-199a-3p is a newly biomarker for diagnosis and novel prognostic indicator in colorectal cancer. However, the miR-199a-3p regulatory mechanism and its target genes are still unclear. In our present study, we demonstrated miR-199a-3p could directly target 3'-UTR of NLK gene by luciferase reporter assay and western blot analysis. We detected NLK expressions in 92 colorectal cancer cases to evaluate its clinicopathologic characteristics in colorectal cancer. Our results showed that NLK expression was significantly downregulated in cancer tissues than NATs, and NLK low-expression was associated with lymph node metastasis, venous invasion, liver metastasis and the TNM stage (P< 0.05). Moreover, Kaplan-Meier analysis showed that low expression of NLK correlated with a shorter overall survival rates of patients with CRC (P< 0.05). In vitro, we also found that NLK suppressed the biological behaviors of colorectal cancer cells, including the abilities of cell proliferation, clone formation, wound healing, migration and invasion (P< 0.05), while overexpression of NLK increased the apoptotic rate of colorectal cancer cells. All these results suggested that NLK was an identified miR-199a-3p target gene and functioned as a tumor suppressor gene in colorectal cancer. NLK could be a novel direction for developing diagnostic and therapeutic approaches in colorectal cancer.
机译:我们先前曾报道miR-199a-3p是大肠癌诊断的新生物标记和新的预后指标。但是,miR-199a-3p的调控机制及其靶基因仍不清楚。在我们目前的研究中,我们证明了miR-199a-3p可以通过荧光素酶报告基因检测和Western blot分析直接靶向NLK基因的3'-UTR。我们检测了92例结直肠癌病例中的NLK表达,以评估其在结直肠癌中的临床病理特征。我们的结果表明,与NATs相比,NLK在癌症组织中的表达明显下调,而NLK的低表达与淋巴结转移,静脉浸润,肝转移和TNM分期有关(P <0.05)。此外,Kaplan-Meier分析表明,NLK的低表达与CRC患者的总体生存率较短相关(P <0.05)。在体外,我们还发现NLK抑制了结直肠癌细胞的生物学行为,包括细胞增殖,克隆形成,伤口愈合,迁移和侵袭的能力(P <0.05),而NLK的过表达增加了结直肠癌的凋亡率。细胞。所有这些结果表明NLK是已鉴定的miR-199a-3p靶基因,并在大肠癌中用作肿瘤抑制基因。 NLK可能是开发结直肠癌诊断和治疗方法的新方向。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号